In the case of suspected AMI, prompt treatment is essential. Patients with NSTEMI who had other initial diagnoses had a significant 14% reduction in their time to death.1
High-sensitivity cardiac troponins are the preferred standards for establishing a biomarker diagnosis of AMI, allowing for more accurate detection and exclusion of myocardial injury according to the 2021 AHA/ACC Chest Pain Guidelines.2 Troponin is the gold standard to distinguish between AMI and non-AMI patients.3-4